Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Big drugmaker. High dividend yield. Promising new products.
All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. Past performance doesn't necessarily make one stock better than the other, though. Which of these big pharma stocks is the smarter pick for investors now? Here's how AbbVie and GlaxoSmithKline compare.
Source: Fool.com
GSK plc ADR Aktie
Die Community bevorzugt leicht GSK plc ADR mit mehr Buy- als Sell-Einschätzungen.
Das niedrigere Kursziel von 35 € im Vergleich zum aktuellen Kurs von 38.2 € für GSK plc ADR führt zu einem negativen Potenzial von -8.38%.